GU Cancers 2020 | Key RCC data: JAVELIN Renal 101 & CheckMate 214

Name: Key RCC data: JAVELIN Renal 101 & CheckMate 214
Uploaded: 2020-02-13T00:00:00.000Z
Duration: 1 min 2 s
Description: Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, gives his opinion on the key kidney cancer data to be taken away from this meeting. Dr Msaouel highlights the JAVELIN Renal 101 (NCT02684006) and CheckMate 214 (NCT02231749) trials, as well as new therapies. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Pavlos Msaouel • 13 Feb 2020

GU Cancers 2020

Genitourinary Cancer Kidney Cancer Sitravatinib

CheckMate 214 JAVELIN Renal 101

Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, gives his opinion on the key kidney cancer data to be taken away from this meeting. Dr Msaouel highlights the JAVELIN Renal 101 (NCT02684006) and CheckMate 214 (NCT02231749) trials, as well as new therapies. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.